A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

AbbVie and its subsidiary Allergan have had a long run of unchallenged success in the market with cosmetic and therapeutic ...

A federal jury in Delaware found that Revance's rival product infringed patents for Allergan's market-leading neurotoxin ...

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the 2025 class of entrepreneurs who will participate in ...

A federal jury July 18 said Revance Therapeutics' skin medication infringed on patents for anti-wrinkle treatment Botox and owes AbbVie-owned Allergan $56 million.

Pfizer and Allergan said the effective tax rate of the new company would be 17% to 18%, well below Pfizer’s effective tax rate last year of 25.5%.

Actavis is nearing a deal to acquire Allergan in a tie-up that would likely be the year’s largest and could help shield the Botox maker from hostile suitor Valeant.

AbbVie announced it will buy Allergan for $63 billion, combining the companies behind Humira and Botox and creating yet another pharmaceutical behemoth. Allergan, with 2018 revenue of $15.8 ...

Allergan sells 30 capsules of its Alzheimer’s drug Namenda XR for about $440, according to the price-comparison site GoodRX. The price was boosted by about 10% at the beginning of the year.

U.S. pharmaceutical giant Pfizer (PFE) and Irish rival Allergan (AGN) Monday announced a record-breaking $160-billion merger, the largest in health-care industry history and the biggest yet ...

Allergan agreed to acquire Tobira Therapeutics, a biopharmaceutical company that develops therapies for liver diseases, in a deal worth as much as $1.7 billion, or 19 times Tobira’s previous ...